Novo Nordisk AS (XTER:NOV)
€ 99.51 -3.09 (-3.01%) Market Cap: 442.81 Bil Enterprise Value: 440.41 Bil PE Ratio: 35.07 PB Ratio: 27.45 GF Score: 91/100

Novo Nordisk A/S Virtual R&D Investor Call (Q&A) Transcript

Jun 19, 2020 / 02:00PM GMT
Release Date Price: €30.2 (+2.74%)
Karsten Munk Knudsen;S;Executive VP
Novo Nordisk A;CFO & Member of the Management Board

/- -

Welcome back to the Novo Nordisk virtual R&D investor presentation. Now we're on to the Q&A session. (Operator Instructions)

And then I will orchestrate the meeting from here.

Questions & Answers

Karsten Munk Knudsen;S;Executive VP
Novo Nordisk A;CFO & Member of the Management Board

/- -

(Operator Instructions) So we're ready to take the first question. And the first question goes to Martin Parkhøi from Danske Bank.

Martin ParkhÃ;i;S
Danske Bank A;Research Division - Senior Equity Analyst

¸ - / -

As Karsten said, it's Martin Parkhøi from Danske Bank. Firstly, I think is focused on the obesity mass. I guess, the Phase I trial that was in a loose combination. Could you talk a bit about the device for later-stage trials? We know it needs to be a dual-chamber device, but

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot